Antibody-drug conjugates (ADCs) represent a groundbreaking advancement in targeted cancer therapy, merging the specificity of monoclonal antibodies with the potency of cytotoxic drugs. By leveraging the unique properties of antibodies, ADCs selectively deliver highly concentrated doses of chemotherapy to cancer cells while minimizing damage to healthy tissues. This approach not only enhances...